Jafron Biomedical (China) Investor Sentiment

300529 Stock   26.05  0.26  1.01%   
About 52% of Jafron Biomedical's investor base is interested to short. The analysis of overall sentiment of trading Jafron Biomedical Co stock suggests that many investors are impartial at this time. The current market sentiment, together with Jafron Biomedical's historical and current headlines, can help investors time the market. In addition, many technical investors use Jafron Biomedical stock news signals to limit their universe of possible portfolio assets.
  
few days ago at news.google.com         
Jafron Biomedical Co.,Ltd. insiders have significant skin in the game with 51 percent ownership - Si...
Google News at Macroaxis
over a month ago at news.google.com         
The past five years for Jafron BiomedicalLtd investors has not been profitable - Simply Wall St
Google News at Macroaxis
over two months ago at news.google.com         
Potential Upside For Jafron Biomedical Co.,Ltd. Not Without Risk - Simply Wall St
Google News at Macroaxis
over two months ago at news.google.com         
Potential Upside For Jafron Biomedical Co.,Ltd. Not Without Risk - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Jafron BiomedicalLtd Seems To Use Debt Rather Sparingly - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
The one-year returns for Jafron BiomedicalLtds shareholders have been favorable, yet its earnings gr...
Google News at Macroaxis
over three months ago at news.google.com         
Should Weakness in Jafron Biomedical Co.,Ltd.s Stock Be Seen As A Sign That Market Will Correct The ...
Google News at Macroaxis
over six months ago at news.google.com         
The three-year shareholder returns and company earnings persist lower as Jafron BiomedicalLtd stock ...
Google News at Macroaxis
over six months ago at news.google.com         
The three-year shareholder returns and company earnings persist lower as Jafron BiomedicalLtd stock ...
Google News at Macroaxis
over six months ago at news.google.com         
Jafron Biomedical Co.,Ltd.s Stock Has Seen Strong Momentum Does That Call For Deeper Study Of Its Fi...
Google News at Macroaxis
over six months ago at news.google.com         
Jafron BiomedicalLtds Dividend Will Be Reduced To CN0.40 - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Interested In Jafron BiomedicalLtds Upcoming CN0.40 Dividend You Have Three Days Left - Simply Wall ...
Google News at Macroaxis
over six months ago at news.google.com         
Why Investors Shouldnt Be Surprised By Jafron Biomedical Co.,Ltd.s 30 percent Share Price Surge - Si...
Google News at Macroaxis
over six months ago at news.google.com         
Jafron BiomedicalLtds Soft Earnings Dont Show The Whole Picture - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Jafron BiomedicalLtd First Quarter 2024 Earnings EPS CN0.35 - Simply Wall St
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Jafron Biomedical that are available to investors today. That information is available publicly through Jafron media outlets and privately through word of mouth or via Jafron internal channels. However, regardless of the origin, that massive amount of Jafron data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jafron Biomedical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jafron Biomedical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jafron Biomedical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jafron Biomedical alpha.

Jafron Biomedical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Jafron Stock analysis

When running Jafron Biomedical's price analysis, check to measure Jafron Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jafron Biomedical is operating at the current time. Most of Jafron Biomedical's value examination focuses on studying past and present price action to predict the probability of Jafron Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jafron Biomedical's price. Additionally, you may evaluate how the addition of Jafron Biomedical to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios